CAJ | 학술논문

胸腺瘤是一类具有广谱生物学行为的罕见肿瘤。对局部晚期胸腺瘤采用新辅助化放疗，可缩小肿瘤或降低分期，提高手术完整切除率。对于无手术指征或远处转移的胸腺瘤给予姑息性化放疗，有助于延长生存期和提高生活质量。最为广泛使用的化疗方案是以顺铂和蒽环类药物为基础的联合方案。近年来陆续尝试新一代化疗药物，包括紫杉醇、多西他赛、卡培他滨、吉西他滨和培美曲赛等，均显示一定疗效。
흉선류시일류구유엄보생물학행위적한견종류。대국부만기흉선류채용신보조화방료，가축소종류혹강저분기，제고수술완정절제솔。대우무수술지정혹원처전이적흉선류급여고식성화방료，유조우연장생존기화제고생활질량。최위엄범사용적화료방안시이순박화은배류약물위기출적연합방안。근년래륙속상시신일대화료약물，포괄자삼순、다서타새、잡배타빈、길서타빈화배미곡새등，균현시일정료효。
Thymoma is a rare tumor with a broad spectrum of biological behavior. For locally advanced thymoma, neoadjuvant chemoradiotherapy can reduce tumor staging and improve surgical resection rate. For unresectable advanced thymomas or metastatic thymomas, palliative radiotherapy and chemotherapy can prolong survival and improve quality of life. The most widely used chemotherapy regimen is cisplatin and marcellomycin drug-based combination chemotherapy scheme. In recent years, a new generation of chemotherapeutic drugs has been tried continually in clinic, including paclitaxel, docetaxel, capecitabine, gemcitabine and alimta, which show a certain therapeutic effect.